Paper Details

  1. Home
  2. Paper Details

Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension.

Author: JohnsonM L, SimonG

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Nebivolol is a new beta 1-adrenoceptor antagonist that is ten times more potent than atenolol at lowering blood pressure. In a study of 25 men with essential hypertension, nebivolol and atenolol were equally effective in reducing blood pressure and heart rate at rest and during exercise. Nebivolol is an effective antihypertensive agent.
Paper Details　
Original Abstract of the Article :
dl-nebivolol is a new, chemically unique, selective beta 1-adrenoceptor antagonist, without sympathomimetic activity. In the present study, the antihypertensive and negative chronotropic effects of 5 and 10 mg once-daily nebivolol were compared to those of 50 and 100 mg once-daily atenolol in 25 whi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/10641969309041625

データ提供：米国国立医学図書館（NLM）

Nebivolol vs. Atenolol: A Comparative Study of Antihypertensive Effects

In the field of [cardiology], finding effective and safe treatments for [essential hypertension] remains a priority. This study, much like a camel navigating a challenging desert landscape, compares the [antihypertensive] and [beta 1-adrenoceptor antagonist] effects of [nebivolol] and [atenolol], two commonly used drugs for managing hypertension. The authors conducted a [double-blind, crossover study] to evaluate the relative efficacy of these two drugs, providing valuable insights for clinicians making treatment decisions.

Nebivolol: A Potent and Effective Antihypertensive Beta-Blocker

The study's findings, like a desert oasis offering a refreshing respite, demonstrate that [nebivolol] is an effective and potent antihypertensive [beta-adrenoceptor antagonist]. On a weight-for-weight basis, nebivolol was [ten times more potent] than atenolol in reducing blood pressure. The study's results, akin to a camel finding a hidden source of water in a dry desert, offer a promising alternative for managing hypertension.

Navigating the Choice of Beta-Blockers for Hypertension Management: Understanding Individual Needs

This study, much like a desert traveler carefully choosing its path through a sandy landscape, highlights the importance of considering individual patient characteristics when selecting a beta-blocker for hypertension management. The authors' findings demonstrate that nebivolol is a potent and effective antihypertensive agent, but further research is needed to fully understand its long-term efficacy and safety in diverse patient populations.

Dr. Camel's Conclusion

This study, much like a camel navigating a challenging desert landscape, compares the antihypertensive and beta 1-adrenoceptor antagonist effects of nebivolol and atenolol, two commonly used drugs for managing hypertension. The authors conducted a double-blind, crossover study to evaluate the relative efficacy of these two drugs, providing valuable insights for clinicians making treatment decisions.

Date :
  1. Date Completed 1993-06-11
  2. Date Revised 2019-11-01
Further Info :

Pubmed ID

8098243

DOI: Digital Object Identifier

10.3109/10641969309041625

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.